Patents by Inventor James ROACHE

James ROACHE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA
    Publication number: 20230183286
    Abstract: The disclosure relates to nucleic acids that contain modifications at the 5?-end, 3?-end or 5?-end and 3?-ends, and compounds that can be used to make the modified nucleic acids are disclosed. The modified nucleic acids have improved expression, lower immunogenicity and improved stability compared to unmodified nucleic acids.
    Type: Application
    Filed: August 16, 2022
    Publication date: June 15, 2023
    Inventors: David BARNES-SEEMAN, Scott Louis COHEN, John Louis DIENER, Christian GAMPE, James ROACHE, Amy White, Sarah Louise Williams, Jun Yuan, Frederic Zecri
  • 3? end caps, 5? end caps and combinations thereof for therapeutic RNA
    Patent number: 11466048
    Abstract: The disclosure relates to nucleic acids that contain modifications at the 5?-end, 3?-end or 5?-end and 3?-ends, and compounds that can be used to make the modified nucleic acids are disclosed. The modified nucleic acids have improved expression, lower immunogenicity and improved stability compared to unmodified nucleic acids.
    Type: Grant
    Filed: February 26, 2020
    Date of Patent: October 11, 2022
    Assignee: NOVARTIS AG
    Inventors: David Barnes-Seeman, Scott Louis Cohen, John Louis Diener, Christian Gampe, James Roache, Amy White, Sarah Louise Williams, Jun Yuan, Frederic Zecri
  • NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA
    Publication number: 20200190132
    Abstract: The disclosure relates to nucleic acids that contain modifications at the 5?-end, 3?-end or 5?-end and 3?-ends, and compounds that can be used to make the modified nucleic acids are disclosed. The modified nucleic acids have improved expression, lower immunogenicity and improved stability compared to unmodified nucleic acids.
    Type: Application
    Filed: February 26, 2020
    Publication date: June 18, 2020
    Inventors: David BARNES-SEEMAN, Scott Louis COHEN, John Louis DIENER, Christian GAMPE, James ROACHE, Amy WHITE, Sarah Louise WILLIAMS, Jun YUAN, Frederic ZECRI
  • 3? end caps, 5? end caps and combinations thereof for therapeutic RNA
    Patent number: 10676499
    Abstract: The disclosure relates to nucleic acids that contain modifications at the 5?-end, 3?-end or 5?-end and 3?-ends, and compounds that can be used to make the modified nucleic acids are disclosed. The modified nucleic acids have improved expression, lower immunogenicity and improved stability compared to unmodified nucleic acids.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: June 9, 2020
    Assignee: NOVARTIS AG
    Inventors: David Barnes-Seeman, Scott Louis Cohen, John Louis Diener, Christian Gampe, James Roache, Amy White, Sarah Williams, Jun Yuan, Frederic Zecri
  • NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA
    Publication number: 20180002368
    Abstract: The disclosure relates to nucleic acids that contain modifications at the 5?-end, 3?-end or 5?-end and 3?-ends, and compounds that can be used to make the modified nucleic acids arc disclosed. The modified nucleic acids have improved expression, lower immunogenicity and improved stability compared to unmodified nucleic acids.
    Type: Application
    Filed: December 16, 2015
    Publication date: January 4, 2018
    Inventors: David BARNES-SEEMAN, Scott Louis COHEN, John Louis DIENER, Christian GAMPE, James ROACHE, Amy WHITE, Sarah WILLIAMS, Jun YUAN, Frederic ZECRI